Rapamycin Treatment for Benign Multicystic Peritoneal Mesothelioma: A Rare Disease with a Difficult Management
article
OA: hybrid
CC0
Abstract
BACKGROUND Benign multicystic peritoneal mesothelioma (BMPM) is a rare intra-abdominal tumor. Although considered by many to be benign, this tumor has a high local recurrence rate. Because of its rarity, preoperative diagnosis is difficult and its origin and pathogenesis are uncertain. There are no evidence-based treatment strategies for BMPM. It is agreed that the best treatment strategy for BMPM is the combination of surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). An increasing body of evidence supports a pivotal role of the cytoplasmic serine/threonine kinase mTOR in the development and progression of several neoplastic diseases and specific mTOR inhibitors, including rapamycin, have been suggested as potential therapeutic options for different cancers. CASE REPORT A 65-year-old male with end-stage renal disease on hemodialysis for seven years presented with BMPM. He underwent surgery to remove multiple peritoneal cysts, but four months later he experienced a recurrence of the disease. Immunohistochemistry of the cysts demonstrated a high level of phosphorylation of p70S6 kinase, a downstream mTOR target, and since a target therapy that blocks PI3K/Akt/mTOR pathway has been shown to have a scientific and logical rationale to treat this rare intra-abdominal neoplasia, we started the patient on low dose rapamycin therapy, an mTOR inhibitor. Long-term mTOR inhibition resulted in a complete and stable remission of BMPM. CONCLUSIONS The current case is the first report of BMPM successfully treated with rapamycin, which resulted in a long-lasting response to mTOR inhibition.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (49)
- W161243551 via openalex
- W1510910605 via openalex
- W1964098989 via openalex
- W1965512467 via openalex
- W1978896961 via openalex
- W1986834944 via openalex
- W1987484454 via openalex
- W1989218189 via openalex
- W1990509102 via openalex
- W2011879153 via openalex
- W2016798792 via openalex
- W2017018900 via openalex
- W2026351725 via openalex
- W2035737532 via openalex
- W2035905423 via openalex
- W2036486988 via openalex
- W2039490470 via openalex
- W2042724367 via openalex
- W2046664530 via openalex
- W2050988292 via openalex
- W2056319408 via openalex
- W2058562532 via openalex
- W2065825082 via openalex
- W2067288907 via openalex
- W2067837009 via openalex
- W2070736508 via openalex
- W2075206562 via openalex
- W2080100938 via openalex
- W2086612793 via openalex
- W2092684826 via openalex
- W2113469452 via openalex
- W2139929303 via openalex
- W2142549862 via openalex
- W2143645520 via openalex
- W2147028601 via openalex
- W2147960762 via openalex
- W2148258332 via openalex
- W2155428653 via openalex
- W2155759619 via openalex
- W2171241440 via openalex
- W2174827322 via openalex
- W2187458554 via openalex
- W2297358564 via openalex
- W2305506986 via openalex
- W2341725703 via openalex
- W2396049700 via openalex
- W2417773697 via openalex
- W2537093953 via openalex
- W2558398627 via openalex
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0
· commercial use OK